ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).

Ashley  Hamilton

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Robin Kate  Kelley

Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Elevar Therapeutics; Exelixis/Ipsen (Inst); J-Pharma; Kinnate Biopharma; Merck (Inst); Moderna Therapeutics; Regeneron; Tyra Biosciences

Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Compass Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); SERVIER (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Merck

Daneng  Li

Consulting or Advisory Role - Abbvie; AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Merck; Sumitomo Pharma Oncology; Tersera; TransThera Biosciences; TriSalus Life Sciences

Speakers' Bureau - Eisai; Exelixis; Ipsen; SERVIER; Tersera

Research Funding - AstraZeneca (Inst)

Ignacio  Melero Bermejo

Honoraria - PharmaMar

Consulting or Advisory Role - Alligator Bioscience; Amunix; AstraZeneca/MedImmune; BiolineRx; Boston Pharmaceuticals; Bright Peak Therapeutics; Bristol-Myers Squibb; Catalym; Curon Biopharmaceutical; Dompé farmaceutici; EMD Serono; F-star; Genmab; Genmab; GlaxoSmithKline; Gossamer Bio; Hookipa Pharma; ImmuneSensor Therapeutics; Merus; Moderna Therapeutics; Monopteros Therapeutics; MSD; Noxxon Pharma; Numab; Pieris Pharmaceuticals; Roche/Genentech; Sanofi; SERVIER; Shattuck Labs

Research Funding - Alligator Bioscience; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Roche/Genentech

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche/Genentech

Ghassan K.  Abou-Alfa

Consulting or Advisory Role - Abbvie; AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Eisai; Exelixis; Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Neogene Therapeutics (I); Novartis (I); QED Therapeutics; Roche/Genentech; Servier; Tempus (I); Vector Health; Yiviva

Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)

Olatunji B.  Alese

No Relationships to Disclose

Raed Moh'd Taiseer  Al-Rajabi

Stock and Other Ownership Interests  - Actinium Pharmaceuticals; Seagen

Consulting or Advisory Role - AstraZeneca; Bayer

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lexicon (Inst); Lilly (Inst); Merck (Inst); Sillajen (Inst)

Hani M.  Babiker

Consulting or Advisory Role - Celgene; Endocyte; Idera; Myovant Sciences; Novocure

Speakers' Bureau - Guardant Health

Mitesh  Borad

Consulting or Advisory Role - BJ Bioscience; Genentech; Imvax; Kriya Therapeutics; Lynx Group; Merck; Senti Biosciences; Tempus; Zymeworks

Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Basilea (Inst); Biond (Inst); Celgene (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Merck Serono (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Senhwa Biosciences (Inst); SillaJen (Inst); Taiho Pharmaceutical (Inst); ZielBio (Inst)

Farshid  Dayyani

Employment - Roche (I)

Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis

Speakers' Bureau - Astellas Pharma; Exelixis; ipsen; SERVIER; Sirtex Medical

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)

Martin  Gutierrez

Stock and Other Ownership Interests  - Cota Healthcare

Consulting or Advisory Role - Celularity; Guardant Health; Sanofi

Speakers' Bureau - BMS; Merck

Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)

Jung Yong  Hong

Honoraria - AstraZeneca; AstraZeneca; Dong-A Socio

Consulting or Advisory Role - AstraZeneca; Eisai

Lionel Aurelien  Kankeu Fonkoua

Honoraria - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)

Consulting or Advisory Role - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)

Thomas Benjamin  Karasic

Honoraria - AstraZeneca/MedImmune; Elevar Therapeutics; Incyte; Ipsen; Pfizer; Taiho Oncology

Consulting or Advisory Role - Incyte; Nucorion Pharmaceuticals

Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); H3 Biomedicine (Inst); Incyte (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst); Tempest Therapeutics (Inst); Totus Medicines (Inst); Xencor (Inst)

Adel  Kardosh

Consulting or Advisory Role - Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Eisai; Genentech; Seagen

Research Funding - Natera

Bridget P.  Keenan

Employment - Astellas Pharma (I)

Consulting or Advisory Role - Regeneron

Research Funding - Partner Therapeutics (Inst)

Travel, Accommodations, Expenses - Genentech/Roche

Anne M.  Noonan

Consulting or Advisory Role - AstraZeneca; AstraZeneca (I); Deciphera (I); Eisai; Elevar Therapeutics; Exelixis; GOG Foundation (I); Helsinn Healthcare; Immunogen (I); Merck (I); OncLive/MJH Life Sciences; OncLive/MJH Life Sciences (I); QED Therapeutics; Taiho Pharmaceutical

Anwaar  Saeed

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer

Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)

Attilio  Bondanza

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Patents, Royalties, Other Intellectual Property - San Raffaele Hospital (Inst)

John  Stone

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca; GlaxoSmithKline

Consulting or Advisory Role - AdoRx (I); Epidarex Capital (I); NeoPhore (I)